Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF) (2010 - 2026)

Sarepta Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 6.17% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $45.1 million, a 15.86% increase from a year earlier, with the FY2025 full-year figure at $44.5 million, up 18.02% from the prior year.
• Depreciation & Amortization (CF) advanced to $10.6 million in Q1 2026 per SRPT's latest filing, from $5.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $18.4 million in Q3 2025 and bottomed at $5.3 million in Q4 2025.
• The 5-year median for Depreciation & Amortization (CF) is $10.6 million (2026), against an average of $10.5 million.
• Biggest YoY gain for Depreciation & Amortization (CF) was 88.15% in 2025; the steepest drop was 49.76% in 2025.
• Year by year, Depreciation & Amortization (CF) stood at $10.6 million in 2022, then gained by 7.76% to $11.4 million in 2023, then fell by 8.06% to $10.5 million in 2024, then plunged by 49.76% to $5.3 million in 2025, then surged by 101.68% to $10.6 million in 2026.
• Per Business Quant, the three latest SRPT Depreciation & Amortization (CF) figures stand at $10.6 million (Q1 2026), $5.3 million (Q4 2025), and $18.4 million (Q3 2025).